Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model (HBM-GCS)

13 novembre 2026 mis à jour par: LI Caixia, Chinese University of Hong Kong

Development of a Gastric Cancer Screening Intervention Program for Helicobacter Pylori Carriers Based on the Health Belief Model

Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.

Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:

(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.

Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:

(1) Q&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.

Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.

Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.

Type d'étude

Interventionnel

Inscription (Estimé)

70

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Guangdong
      • Shenzhen, Guangdong, Chine, 518000
        • The University of Hong Kong-Shenzhen Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

45 ans à 74 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Aged between 45 and 74 years.
  2. Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
  3. Have adequate communication, reading, and comprehension ability.
  4. Provide informed consent, voluntarily participate in the study, and cooperate with all study procedures.

Exclusion Criteria:

  • 1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.

    3. Pregnant or breastfeeding women.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Dépistage
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental: Health Belief Model-based intervention group

Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals.

Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals.

Autre: Control group

Usual care provided by the hospital, including one-page written education material on gastroscopy.

Usual care provided by the hospital, including one-page written education material on gastroscopy.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Gastric cancer screening intention
Délai: Immediately and 6 weeks after intervention

Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years.

Immediately and 6 weeks after intervention
Gastroscopy completion rate
Délai: 6 weeks after intervention

An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior.

6 weeks after intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Gastric cancer screening knowledge score
Délai: Immediately and 6 weeks after intervention

Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms.

Immediately and 6 weeks after intervention
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
Délai: Immediately and 6 weeks after intervention

This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated.

Immediately and 6 weeks after intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Mengyao Gao, MN, Kiang Wu Nursing College of Macau(KWNC)

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

25 novembre 2026

Achèvement primaire (Estimé)

31 mars 2027

Achèvement de l'étude (Estimé)

31 mars 2027

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner